UiPath Announces AI Partnership with Google Cloud to Transform Medical Processes | PATH Stock News

Author's Avatar
Apr 09, 2025
  • UiPath (PATH, Financial) partners with Google Cloud to introduce an AI-driven Medical Record Summarization agent.
  • The AI solution reduces prior authorization times by up to 50% and saves 40 minutes per patient referral.
  • Initial deployment showcases a 23% faster document processing for a major healthcare payer.

UiPath (PATH), a notable enterprise automation and AI software company, has announced a collaboration with Google Cloud to unveil its generative AI-based Medical Record Summarization agent. Powered by Google Cloud's Vertex AI and Gemini models, this innovative solution aims to revolutionize medical processes by significantly reducing the time needed for prior authorization from 45 minutes to mere minutes.

This technological advancement is anticipated to cut prior authorization turn-around time by up to 50%, allowing healthcare organizations to save up to 40 minutes per patient referral. Aimed at streamlining tasks such as patient referral intake and utilization management reviews, the AI agent provides clinician-level summaries with traceable data, thus enhancing the accuracy of clinical decisions.

Currently in private preview, the AI solution has already demonstrated its efficacy with a major healthcare payer, achieving document processing speeds that are 23% faster. By leveraging Google Cloud's Vertex AI and Gemini 2.0 Flash, the agent utilizes state-of-the-art retrieval-augmented generation (RAG) to efficiently handle unstructured medical data, ensuring consistent quality and standardized medical summaries.

This partnership represents UiPath's strategic focus on delivering vertical AI solutions tailored to specific industry needs. UiPath, known for transforming business operations with sophisticated AI technology, continues to enhance how industries innovate and compete in a rapidly advancing technological landscape.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.